



## Cancer Prevention and Control Central IRB

### Meeting Agenda

Thursday, May 25, 2017  
9:00 am –12:25 pm Eastern Time

#### Agenda

---

---

##### I. General Business

- Next Meeting: Thursday, June 22, 2017
  - Tobacco and Alcohol Assessments in Consortia studies
- 

##### II. Reports for 04/01/17 – 04/30/17

- CPC CIRB Local Context Subcommittee Report
  - Expedited Reviews and Study Acknowledgements
  - Study Activation Acknowledgements
  - Amendment Activation Acknowledgements
- 

##### III. Review/Approval of Minutes

- April 27, 2017
- 
- 

##### IV. Continuing Review

**MAY2015-05-01**, Randomized, double-blind, placebo-controlled trial of Meriva® (curcumin) as a candidate chemoprevention agent for gastric carcinogenesis (Version 4, Amendment 1, Protocol Version 08/23/16)

---

---

##### V. Amendment Review

**MAY2015-05-01**, Randomized, double-blind, placebo-controlled trial of Meriva® (curcumin) as a candidate chemoprevention agent for gastric carcinogenesis (Version 4, Amendment 2, Protocol Version 04/14/17)

---

---

##### VI. Amendment Review

**S1501**, Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III (Protocol Version 12/23/16)

---

---

##### VII. Amendment Review

**UW12016-07-01**, Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus met® XR in Subjects with Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment (Protocol Version 05/01/17)

---

---

##### VIII. Amendment Review

**MAY2016-07-01**, Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis (Protocol Version 05/01/17)

**IX. Initial Review**

**MAY2016-08-01**, A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer (Protocol Version 04/18/17)

---

**X. Initial Review**

**URCC 16070**, Treatment of Refractory Nausea (Protocol Version 04/10/17)

---